Recombinant Mouse Coagulation Factor XIV/PROC Protein，His & GST

Coagulation Factor XIV, also known as Protein C (PROC), plays a crucial role in the regulation of blood coagulation and the inflammatory response. It is produced in the liver and is activated to activated Protein C (APC) by thrombin in the presence of thrombomodulin. The activated Protein C serves as an anticoagulant, limiting clot formation and facilitating fibrinolysis, thus maintaining hemostatic balance. Research into recombinant PROC focuses on its therapeutic potential in treating various clotting disorders and thromboembolic diseases, particularly in patients with Protein C deficiency or severe coagulopathies. Given the complexities associated with traditional therapeutic agents—such as their limited efficacy, risk of bleeding complications, and challenging dosing protocols—advancements in recombinant technologies hold promise for the development of safer and more effective treatments. Recent studies emphasize the importance of optimizing recombinant PROC production systems to achieve high yields and proper post-translational modifications. Continued investigation into the pharmacodynamics and clinical applications of recombinant PROC aims to enhance our understanding of its anticoagulant mechanisms while overcoming the limitations of existing therapies, potentially leading to improved outcomes for individuals affected by coagulation abnormalities.